Spero Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Spero Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Spero Therapeutics, Inc. (SPRO) Q2 2023 Earnings Call Transcript
Investors are testing whether Spero Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Spero Therapeutics, Inc. Investor News: Robbins LLP is Investigating Spero Therapeutics, Inc. (SPRO) on Behalf of Shareholders
Investors are testing whether Spero Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest SPRO filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Spero Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →